Ten Houston companies received funding from the Founders First CDC's Job Creators Quest Grant. Photo courtesy

A national nonprofit has granted $100,000 in funding to 31 companies across the state. Ten of the recipients are based in Houston.

Founders First CDC — an organization that supports diverse founder-led, revenue-generating businesses — named the winners of its new Job Creators Quest Grant this week. Over 600 Texas businesses applied, and the selected recipients represent industries from construction and manufacturing to STEM and healthcare, to hospitality, and more.

"The challenges of simply keeping the doors open have been amplified by an unforeseen obstacle – the pandemic. Now more than ever it takes commitment, perseverance and healthy funding to succeed, which is why I'm excited about Founders First CDC," says Texas State Senator and small business owner, Royce West, in a news release. "This organization is providing small businesses with wherewithal to create jobs, which in turn help sustain operations, achieve business goals and stimulate the economy."

Launched earlier this year, the Job Creators Quest Grant is funding businesses to help them retain and grow their workforce through the pandemic. Since its inception, the program has awarded more than $220,000 to minority and underrepresented business owners throughout the United States.

"We have observed many founders working more in their business than on their business. Our priority is to give entrepreneurs resources to grow while simultaneously becoming premium wage job creators within their community," says Shaylon Scott, executive director of Founders First CDC, in the release. "Investing in diverse entrepreneurs is an impactful way to drive job and wealth creation in underserved communities. The Job Creators Quest Grant is more than a dollar amount, it's a celebration of their success."

Eligibility requirements included the company's founder must be Black, indigenous, a person of color, LGBTQIA+, military veteran, woman or located in a low to moderate income area and be a for-profit company with annual revenues between $100,000 to $3 million. Grant winners will use the funds to help create and add 1-2 net new premium wage jobs in the next 12 months. The program was funded by a $1 million grant from the Rockefeller Foundation, along with Founders First CDC Capital Partners' recent $9 million series A.

The Houston companies that received funding were:

  • DM Electrical and Construction LLC - $10,000
  • Medley Inc. - $10,000
  • EFS GROUP PLLC - $2,500
  • AtWork Personnel Services - $2,500
  • Camellia Alise, LLC - $1,500
  • Flava Wings - $1,500
  • Oops Steam Cleaning - $1,500
  • The Body: A Home for Love - $1,500
  • TNR Accounting & Management Consulting, LLC - $2,500
  • Socium Solutions LLC - $2,500

The other Texas companies that received grant money were:

  • COCINA 54 (Austin) - $1,500
  • Laundris Corp (Austin) - $1,500
  • Center for Music Therapy, Inc. (Austin) - $1,500
  • Le Rouge Cuisine Food Company (Dallas) - $5,000
  • TDG Scientific (Dallas) - $5,000
  • SCENT & FIRE CANDLE COMPANY (Dallas) - $2,500
  • brittani (Dallas) - $2,500
  • Atmospheric Home Staging (Dallas) - $1,500
  • RD Adams Enterprise LLC dba ONE Elite Staffing (Dallas) - $1,500
  • Civil Pour (Dallas) - $1,500
  • Lalloon Marketing Group, LLC dba Imperium Surgical Partners (Dallas) - $1,500
  • WEST ONE PRODUCTS LLC (Fort Worth) - $1,500
  • Hooked On Code, LLC (Frisco) - $5,000
  • Hustle Clean (Frisco) - $5,000
  • PriceSenz LLC (Irving) - $1,500
  • R2R Palliative and Hospice Care LLC (Lewisville) - $1,500
  • Bernadette Davis Communications (Plano) - $1,500
  • Channel Source Inc (Southlake) - $5,000
  • KoderLabs (Trophy Club) - $1,500
  • Brisco Wheel Repair LLC DBA Alloy Wheel Repair of San Antonio (San Antonio) - $1,500
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”